Skip to content
  • HOME
  • CONFERENCE INFORMATION
    • Welcome Letter
    • Conference Chair
    • General Information
    • Conference Format
    • Target Audience
  • Program
    • Conference Program
    • Speakers
  • ABSTRACTS
    • Call for Abstracts
    • Abstract Topics
    • Instructions for E-Poster Presentations
  • Registration
    • Registration
  • Sponsorship Opportunities
    • Sponsorship Opportunities
    • Sponsors & Exhibitors
  • CONTACT US

Miami Debates in Hematologic Malignancies

Virtual Conference

27 January 2022
Register
Program
  • HOME
  • CONFERENCE INFORMATION
    • Welcome Letter
    • Conference Chair
    • General Information
    • Conference Format
    • Target Audience
  • Program
    • Conference Program
    • Speakers
  • ABSTRACTS
    • Call for Abstracts
    • Abstract Topics
    • Instructions for E-Poster Presentations
  • Registration
    • Registration
  • Sponsorship Opportunities
    • Sponsorship Opportunities
    • Sponsors & Exhibitors
  • CONTACT US
Register
Program

GOLD SPONSOR

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary .

Miami Debates in Hematologic Malignancies

is organized by Bioevents Ltd.

#MDHM2022

Join our online community:
Contact Us

 

US:       +1-857-400-0035
UK:      +44-203-051-4032
Email:  info@bioevents-congress.com

Copyright © 2015 BioEvents.net. All Rights Reserved
Term Of Use
Privacy Policy
Powered By Form Wizard
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Necessary Always Enabled